Show notes
Therapeutic resistance and the risks of progression remain an ongoing challenge for various hematological malignancies, including acute promyelocytic leukemia, chronic myeloproliferative neoplasms, myelodysplastic syndromes, and acute myeloid leukemia.
New comment